Two digital health companies, ORCHA and Cogniss, have announced a partnership aimed at benefiting from the UK-Australia Free Trade Agreement (FTA), which has passed the UK House of Commons and may enter into force this year.
FTAs aim to promote increased trade, two-way investment, economic growth and job creation. It is the first international FTA negotiated from scratch by the British government after Brexit.
ORCHA is a UK based specialist in digital health assessment and delivery. Australia-based Cogniss is a no-code digital health platform that enables innovators to create solutions without coding or technical expertise.
Under the new partnership, apps built through Cogniss’ no-code platform will meet ORCHA Baseline Review standards for data, security and accessibility. This streamlines the app development and evaluation process, empowering medical professionals to develop bespoke content that meets professional assurance standards without the need for advanced technical expertise.
It also helps reduce regulatory and technical barriers and improve quality. This problem has often hampered the introduction of solutions into his NHS and Medicare, Australia’s universal health care system.
At an event hosted by the Australian High Commission hosted by Senator Hong Don Farrell, Fiona Costello, Senior Vice President for Accreditation, ORCHA, said: As such, it relies on commercial products that are not always a perfect match. Alongside Cogniss, we understand the standards for creating quality technology and through this partnership we are now able to support the development of market-ready solutions. ”
Dr. Lloyd Humphreys, Cogniss’ newly appointed managing director, added: “Founding and creating a digital health solution for addiction in 2009 took over two years and a £1 million investment. Since then, nothing has changed in how apps are designed and built. Cogniss represents a complete paradigm shift in the field and working with ORCHA will further accelerate our ability to lower the barriers to creating great technology that solves the challenges facing clinical entrepreneurs. . ”
Cogniss now has its global headquarters in Cambridge with the support of the UK Department for International Trade, the New South Wales Board of Investment and Austrade.